EQS-News: Formycon AG / Key word: Quarter Results/Quarterly / Interim Statement
Formycon reports results for the first quarter 2023
30.05.2023 / 07:30 CET/CEST
The issuer is. | May 30, 2023
Analysts Jefferies initiated Formycon with a buy rating and a price target of 101 euros. The German developer of copycat biopharmaceutical products operates in a market that is expected to grow at an. | May 22, 2023
EQS-Ad-hoc: Formycon AG / Key word: Agreement/Alliance
Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1
01-Feb-2023 / 17:40. | February 1, 2023
DGAP-News: Formycon AG / Key word: AGM/EGM/Miscellaneous
Formycon AG announces amendment to the proposal for election of a Supervisory Board member in the context of the Annual General. | June 28, 2022